Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.

Yamamoto D, Campbell JD.

Autoimmune Dis. 2012;2012:784364. doi: 10.1155/2012/784364. Epub 2012 Dec 6.

2.

Generalisability in economic evaluation studies in healthcare: a review and case studies.

Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, Davies LM, Eastwood A.

Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. Review.

3.

Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.

Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, Douglas G, Muers M, Smith D, White J.

Health Technol Assess. 2001;5(26):1-149. Review.

4.

Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model.

Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C.

Health Technol Assess. 2006 Nov;10(44):iii-iv, ix-x, 1-210. Review.

5.

Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis.

McDaid C, Griffin S, Weatherly H, Durée K, van der Burgt M, van Hout S, Akers J, Davies RJ, Sculpher M, Westwood M.

Health Technol Assess. 2009 Jan;13(4):iii-iv, xi-xiv, 1-119, 143-274. doi: 10.3310/hta13040. Review.

6.

Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population.

Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, Fisk JD, Brown M.

Value Health. 2009 Jul-Aug;12(5):657-65. doi: 10.1111/j.1524-4733.2008.00485.x. Review.

7.

The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.

Clegg AJ, Scott DA, Loveman E, Colquitt J, Hutchinson J, Royle P, Bryant J.

Health Technol Assess. 2005 Nov;9(45):1-132, iii-iv. Review.

8.

The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.

Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, Clegg A.

Health Technol Assess. 2010 Mar;14(19):1-204. doi: 10.3310/hta14190. Review.

9.

'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.

Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D.

Health Technol Assess. 2008 Feb;12(2):iii-iv, ix-xi, 1-135. Review.

10.

Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.

Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, Bayliss S, Roberts T, Burls A.

Health Technol Assess. 2007 Feb;11(6):iii-iv, 1-85. Review.

11.

A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.

Campbell JR, Sasitharan T, Marra F.

Appl Health Econ Health Policy. 2015 Aug;13(4):325-40. doi: 10.1007/s40258-015-0183-4. Review.

PMID:
26129810
12.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

13.

Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.

Menzin J, Caon C, Nichols C, White LA, Friedman M, Pill MW.

J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S24-40. Review.

14.

Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies.

Owens GM, Olvey EL, Skrepnek GH, Pill MW.

J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S41-53. Review.

15.
16.

Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.

Hawton A, Shearer J, Goodwin E, Green C.

Appl Health Econ Health Policy. 2013 Aug;11(4):331-41. doi: 10.1007/s40258-013-0034-0. Review.

PMID:
23637055
17.

Management of frozen shoulder: a systematic review and cost-effectiveness analysis.

Maund E, Craig D, Suekarran S, Neilson A, Wright K, Brealey S, Dennis L, Goodchild L, Hanchard N, Rangan A, Richardson G, Robertson J, McDaid C.

Health Technol Assess. 2012;16(11):1-264. doi: 10.3310/hta16110. Review.

18.

Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies.

Iannazzo S, Iliza AC, Perrault L.

Pharmacoeconomics. 2017 Oct 14. doi: 10.1007/s40273-017-0577-2. [Epub ahead of print] Review.

PMID:
29032493
19.

The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.

Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ.

Health Technol Assess. 2009 Sep;13(41):1-190, 215-357, iii-iv. doi: 10.3310/hta13410. Review.

20.

A systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip.

de Verteuil R, Imamura M, Zhu S, Glazener C, Fraser C, Munro N, Hutchison J, Grant A, Coyle D, Coyle K, Vale L.

Health Technol Assess. 2008 Jun;12(26):iii-iv, ix-223. Review.

Supplemental Content

Support Center